276 related articles for article (PubMed ID: 20187016)
21. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma.
Giovanella L; Ceriani L; Ghelfo A; Keller F
Clin Chem Lab Med; 2005; 43(8):843-7. PubMed ID: 16201895
[TBL] [Abstract][Full Text] [Related]
22. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
23. Prevalence, clinical significance and prognostic value of anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid carcinoma: a retrospective study.
Pedrazzini L; Baroli A; Lomuscio G; Marzoli L
Minerva Endocrinol; 2009 Sep; 34(3):195-203. PubMed ID: 19859043
[TBL] [Abstract][Full Text] [Related]
24. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?
Rosario PW; Mourão GF; dos Santos JB; Calsolari MR
Thyroid; 2014 Mar; 24(3):533-6. PubMed ID: 24067080
[TBL] [Abstract][Full Text] [Related]
25. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment.
Bachelot A; Leboulleux S; Baudin E; Hartl DM; Caillou B; Travagli JP; Schlumberger M
Clin Endocrinol (Oxf); 2005 Mar; 62(3):376-9. PubMed ID: 15730423
[TBL] [Abstract][Full Text] [Related]
26. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
[TBL] [Abstract][Full Text] [Related]
27. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
28. [Prospective therapy study in differentiated thyroid carcinoma].
Gemsenjäger E; Heitz P; Martina B
Schweiz Med Wochenschr; 1995 Nov; 125(46):2226-36. PubMed ID: 8525342
[TBL] [Abstract][Full Text] [Related]
29. The need of prophylactic central lymph node dissection is controversial in terms of postoperative thyroglobulin follow-up of patients with cN0 papillary thyroid cancer.
Korkmaz MH; Öcal B; Saylam G; Çakal E; Bayır Ö; Tutal E; Tatar EÇ
Langenbecks Arch Surg; 2017 Mar; 402(2):235-242. PubMed ID: 28224278
[TBL] [Abstract][Full Text] [Related]
30. Thyroglobulin-guided (131)I ablation in low-risk differentiated thyroid carcinoma: is the yardstick accurate enough?
Giovanella L
Head Neck; 2011 Sep; 33(9):1379-80; author reply 1380-1. PubMed ID: 21739512
[No Abstract] [Full Text] [Related]
31. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.
Frasoldati A; Pesenti M; Gallo M; Caroggio A; Salvo D; Valcavi R
Cancer; 2003 Jan; 97(1):90-6. PubMed ID: 12491509
[TBL] [Abstract][Full Text] [Related]
32. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.
Bonnet S; Hartl D; Leboulleux S; Baudin E; Lumbroso JD; Al Ghuzlan A; Chami L; Schlumberger M; Travagli JP
J Clin Endocrinol Metab; 2009 Apr; 94(4):1162-7. PubMed ID: 19116234
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
[TBL] [Abstract][Full Text] [Related]
34. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
[TBL] [Abstract][Full Text] [Related]
35. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
Bal CS; Kumar A; Pant GS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
[TBL] [Abstract][Full Text] [Related]
36. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
[TBL] [Abstract][Full Text] [Related]
37. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
[TBL] [Abstract][Full Text] [Related]
39. Low versus high activity radioiodine remnant ablation for differentiated thyroid carcinoma with gross extrathyroidal extension invading only strap muscles.
Park SY; Kim HI; Choi JY; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Ahn SH; Kim K; Jeong JG; Kim SW; Chung JH; Kim TH
Oral Oncol; 2018 Sep; 84():41-45. PubMed ID: 30115474
[TBL] [Abstract][Full Text] [Related]
40. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
Mourão GF; Rosario PW; Calsolari MR
Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]